Cited by 1,047Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Open access

Siegal, Deborah M., Curnutte, John T., Connolly, Stuart J., Lu, Genmin, Conley, Pamela B., Wiens, Brian L., Mathur, Vandana S., Castillo, Janice, Bronson, Michele D., Leeds, Janet M., Mar, Florie A., Gold, Alex, Crowther, Mark A.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1510991

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS: Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1510991

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,169
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K. Y., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 700
Self-citation
Probability Tables for Individual Comparisons by Ranking Methods
Wilcoxon, F. (1947) · Biometrics · doi:10.2307/3001946 · Cited by 578
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 450
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Beyer‐Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C. U., Werth, S., Şahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 408
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 310

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

Crowther MA, 2013, J Thromb Haemost, 11, OC 20.1

Sorted by citations

Items 401–500 of 1,000

Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis
Ma, J., Chalasani, N., Schwantes-An, T.-H. L., & Bjornsson, E. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17297 · Cited by 14
Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
Blann, A. D., & Lip, G. Y. H. (2016) · Heart · doi:10.1136/heartjnl-2014-307019 · Cited by 14
Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease
Humbert, X., Roule, V., Chequel, M., Fédrizzi, S., Brionne, M., Lelong‐Boulouard, V., Milliez, P., & Alexandre, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.212 · Cited by 14
Perioperative management of antithrombotic therapies
Yurttas, T., Wanner, P. M., & Filipovic, M. (2017) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000481 · Cited by 15
Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective
Cantú-Brito, C. G., Silva, G. S., & Ameriso, S. F. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617734309 · Cited by 14
Association of Atrial Fibrillation and Oral Anticoagulant Use With Perioperative Outcomes After Major Noncardiac Surgery
Ge, Y., Ha, A. C. T., Atzema, C. L., Abdel-Qadir, H. M., Fang, J., Austin, P. C., Wijeysundera, D. N., & Lee, D. S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006022 · Cited by 14
Antidotes for reversal of direct oral anticoagulants
Dobesh, P. P., Bhatt, S. H., Trujillo, T. C., & Glaubius, K. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107405 · Cited by 14
Is It Truly “Alpha”? Incidence of Thrombotic Events With Andexanet Alfa at a Single Academic Medical Center
Parsels, K. A., Seabury, R. W., Darko, W., Probst, L. A., Cwikla, G. M., & Miller, C. D. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.12.026 · Cited by 14
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)
Zhang, X., Cai, Q., Wang, X., Liao, K., Hu, C., & Chen, H. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02415-5 · Cited by 14
Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect
Nagakari, K., Emmi, M., & Iba, T. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616638506 · Cited by 14
Apixaban to prevent stroke in patients with atrial fibrillation: a review
Peterson, B. E., Al‐Khatib, S. M., & Granger, C. B. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716652787 · Cited by 14
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
Schultz, N. H., Tran, H. T. T., Bjørnsen, S., Henriksson, C. E., Sandset, P. M., & Holme, P. A. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12015 · Cited by 14
Therapeutic Approach to the Critically Poisoned Patient
Schwarz, E. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_63 · Cited by 13
Clickable liposomes for on-demand reversal of antiplatelet drugs: Towards a safe management of bleeding risks associated with antithrombotic therapy
Cheng, X., Wang, C., Xu, J., Huang, Y., Chen, Z., Zhong, L., Du, C., Nie, G., & Zhang, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.070 · Cited by 13
Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and Prothrombin Complex Concentrates
Panos, N. G., Jones, G. M., Cook, A. M., Peksa, G. D., John, S., DeMott, J. M., Tobias, P., da Silva, I. R. F., & on behalf of the Neurocritical Care Society Pharmacy Study Group (2025) · Critical Care Medicine · doi:10.1097/ccm.0000000000006656 · Cited by 13
Managing hip fracture and lower limb surgery in the emergency setting
Fisher, W. (2017) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001453 · Cited by 13
Approaches to Direct Oral Anticoagulant Selection in Practice
Paravattil, B., & Elewa, H. F. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418793137 · Cited by 15
Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference
Favaloro, E. J., Gilmore, G., Bonar, R. A., Dean, E., Arunachalam, S., Mohammed, S., & Baker, R. I. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1160 · Cited by 13
Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
Müther, M., Schwindt, W., Mesters, R. M., Minnerup, J., Stracke, P., Holling, M., Wiendl, H., & Stummer, W. (2022) · Neurocritical Care · doi:10.1007/s12028-022-01573-5 · Cited by 13
Pentasaccharides for the treatment of deep vein thrombosis
Brandão, G. M. S., Junqueira, D. R., Rollo, H. A., & Sobreira, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011782.pub2 · Cited by 13
In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
Körber, M. K., Langer, E., Kaufner, L., Sander, M., & Heymann, C. V. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2016.0205-15 · Cited by 13
Gastrointestinal bleeding secondary to the new anticoagulants
Abraham, N. S., & Horsley‐Silva, J. L. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000310 · Cited by 13
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery
Heard, L. K., Shanahan, C., & Maggio, K. L. (2016) · Dermatologic Surgery · doi:10.1097/dss.0000000000000956 · Cited by 13
Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: The SAMURAI-NVAF study
Yoshimura, S., Sato, S., Todo, K., Okada, Y., Furui, E., Matsuki, T., Yamagami, H., Koga, M., TAKAHASHI, J. C., Nagatsuka, K., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.01.041 · Cited by 13
Catheter ablation for atrial fibrillation: current patient selection and outcomes
Walsh, K., & Marchlinski, F. E. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1510317 · Cited by 13
Andexanet alfa for the reversal of factor Xa inhibitors
Favresse, J., Hardy, M. J., van Dievoet, M., Sennesael, A., Douxfils, J., Samama, C. M., Vornicu, O., Dincq, A.-S., Lessire, S., & Mullier, F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1599355 · Cited by 13
Idarucizumab in major trauma patients: a single centre real life experience
Oberladstätter, D., Voelckel, W., Bruckbauer, M., Zipperle, J., Grottke, O., Ziegler, B., & Schöchl, H. (2019) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-019-01233-y · Cited by 13
Kontribusi Kedisiplinan Belajar, Pola Asuh, dan Fasilitas Belajar Terhadap Hasil Belajar Matematika Selama Pembelajaran Daring
Sudiartini, N. L., Suharta, I. G. P., & Sudiarta, I. G. P. (2021) · Jurnal Imiah Pendidikan dan Pembelajaran · doi:10.23887/jipp.v5i1.31386 · Cited by 13
Andexanet Alfa–Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives
Chabata, C. V., Yu, H., Ke, L., Frederiksen, J. W., Patel, P. A., Sullenger, B. A., & Thalji, N. K. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321650 · Cited by 12
Direct oral anticoagulants in rare venous thrombosis
Finazzi, G., & Ageno, W. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1398-6 · Cited by 12
Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients
Blandino, A., Bianchi, F., Biondi‐Zoccai, G., Grossi, S., Conte, M. R., Rametta, F., & Gaïta, F. (2016) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-016-0141-6 · Cited by 12
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 12
Reversing anti–factor Xa agents and the unmet needs in trauma patients
Hunt, B. J., Neal, M. D., & Stensballe, J. (2018) · Blood · doi:10.1182/blood-2018-06-850396 · Cited by 12
The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations
Wan, D., Healey, J. S., & Simpson, C. S. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.07.476 · Cited by 12
Reversal strategies in patients treated with direct oral anticoagulants
Gressenberger, P. (2019) · VASA · doi:10.1024/0301-1526/a000777 · Cited by 12
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan
Toyoda, Ḱ., Arakawa, S., Ezura, M., Kobayashi, R., Tanaka, Y., Hasegawa, S., Yamashiro, S., Komatsu, Y., Terasawa, Y., Masuno, T., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64223 · Cited by 12
Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.
Amin, A. (2016) · PubMed Central · Cited by 12
Management of neurologic complications of coagulopathies
VanDerWerf, J. D., & Kumar, M. A. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63599-0.00040-5 · Cited by 14
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., BREITHARDT, G. E., Fox, K. A. A., Hacke, W., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.095 · Cited by 12
Reversal Agents in the Era of NOACs: 2017 Update
Sy, R. W. (2017) · Journal of Atrial Fibrillation · doi:10.4022/jafib.1634 · Cited by 12
Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019
Junior, C. V. S., Soeiro, A. D. M., Leal, T. C., Godoy, L. C., Biselli, B., Hata, L. A., Martins, E. B., Manta, I. C. K. A., Tavares, C. A. M., Cardozo, F. A. M., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190128 · Cited by 12
Coordinating emergent procedures after andexanet alfa
Culbreth, S. E., Sylvester, K. W., Rimsans, J., & Connors, J. M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25587 · Cited by 12
What gastroenterologists should know about direct oral anticoagulants
Radaelli, F., Fuccio, L., Paggi, S., Bono, C. D., Dumonceau, J., & Dentali, F. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.04.032 · Cited by 12
An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms
von Drygalski, A., Bhat, V., Gale, A. J., Averell, P. M., Cramer, T. J., Elias, D. J., Griffin, J. H., & Mosnier, L. O. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001699 · Cited by 12
Novel oral anticoagulants for acute coronary syndrome
Robinson, A. M., McCarty, D. J., & Douglas, J. S. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716671484 · Cited by 12
Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement
Helin, T., Virtanen, L., Manninen, M. J., Leskinen, J., Leppilahti, J. I., Joutsi‐Korhonen, L., & Lassila, R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1492-2 · Cited by 13
Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa
Hersi, A. S., Alhebaishi, Y. S., Hamoui, O., Hassan, T., Hamad, A. K., Magdy, M., Sabbour, H. M., & Shaheen, S. M. (2017) · Journal of the Saudi Heart Association · doi:10.1016/j.jsha.2017.05.001 · Cited by 12
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Therapeutic Approach to the Critically Poisoned Patient
Schwarz, E. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_63-1 · Cited by 11
An update on applications and limitations of direct oral anticoagulants
Wei, S., Sawhney, A., Khandait, H. V., Meda, A., Gupta, V., & Jain, R. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00212-5 · Cited by 11
Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician
Lohrmann, G. M., Atwal, D., Augoustides, J. G., Askar, W., Patel, P. A., Ghadimi, K., Makar, G., Gutsche, J. T., Shamoun, F. E., & Ramakrishna, H. (2016) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2016.01.005 · Cited by 11
Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors
Nafee, T., Aslam, A., Chi, G., Pahlavani, S., Nimri, D., Kuchkuntla, A. R., Talib, U., Michalak, N., Daaboul, Y., Korjian, S., et al. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1305889 · Cited by 11
WITHDRAWN: 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Calkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · Journal of Arrhythmia · doi:10.1016/j.joa.2017.07.001 · Cited by 11
2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation
Lee, J., Joung, B., Cha, M., Lee, J. H., Lim, W., Kim, T., Shin, S. Y., Uhm, J., Lim, H. E., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.87.e1 · Cited by 11
Spontaneous spinal subdural haematoma in a patient on apixaban
Mchaourab, A., Evans, G., & Austin, R. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-227311 · Cited by 11
Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban
Abuan, I., Wong, K. H., Bolinske, B., & Hale, K. S. (2019) · Journal of Pharmacy Technology · doi:10.1177/8755122519839437 · Cited by 11
The effect of anticoagulation on outcomes after liver and spleen injuries: A research consortium of New England centers for trauma (ReCONECT) study
Bhattacharya, B., Askari, R., Davis, K. A., Dorfman, J. D., Eid, A., Elsharkawy, A. E. M., Kasotakis, G., Mackey, S., Odom, S. R., Okafor, B. U., et al. (2020) · Injury · doi:10.1016/j.injury.2020.05.002 · Cited by 11
Applications and future of aptamers that achieve rapid-onset anticoagulation
Yu, H., Frederiksen, J. W., & Sullenger, B. A. (2023) · RNA · doi:10.1261/rna.079503.122 · Cited by 11
Management and Prognosis of Acute Stroke in Atrial Fibrillation
Hindsholm, M. F., Damgaard, D., Gurol, M. E., Gaist, D., & Simonsen, C. Z. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175752 · Cited by 11
Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives
Briceno, D. F., Madan, N., Romero, J. E., Jimenez, A. L., Villablanca, P. A., Natale, A., & Biase, L. D. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1325867 · Cited by 11
FXa-α2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo
Jourdi, G., Gouin‐Thibault, I., Siguret, V., Gandrille, S., Gaussem, P., & Bonniec, B. L. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1667014 · Cited by 11
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Plitt, A., Ruff, C. T., & Giugliano, R. P. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.002 · Cited by 11
Optimal Reversal of Novel Anticoagulants in Trauma
Weinberger, J. M., & Cipolle, M. D. (2016) · Critical Care Clinics · doi:10.1016/j.ccc.2016.08.005 · Cited by 11
Direct Oral Anticoagulants: An Overview for the Interventional Radiologist
Kumar, P., Ravi, R., Sundar, G., & Shiach, C. R. (2016) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-016-1521-0 · Cited by 11
Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation
Ueberham, L., Dagres, N., Potpara, T., Bollmann, A., & Hindricks, G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0616-6 · Cited by 11
Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland
Angelillo‐Scherrer, A., Casini, A., Studt, J., Gerber, B., Alberio, L., & Fontana, P. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40113 · Cited by 10
Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage
Grainger, B. T., McFadyen, J. D., & Tran, H. A. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.10.020 · Cited by 10
Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay
Bourti, Y., Fazavana, J., Armand, M., Saller, F., Lasne, D., Borgel, D., & Bianchini, E. P. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-12-0927 · Cited by 10
Spontaneous splenic rupture due to rivaroxaban
Nagaraja, V., Cranney, G., & Kushwaha, V. V. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-223237 · Cited by 10
Coagulation Factor Xa (Recombinant), Inactivated-zhzo (Andexanet Alfa)
Baker, D. E. (2018) · Hospital Pharmacy · doi:10.1177/0018578718788840 · Cited by 10
Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis
Hekman, K. E., Chao, C. L., Morgan, C. E., Helenowski, I., & Eskandari, M. K. (2021) · Vascular · doi:10.1177/17085381211042231 · Cited by 10
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
Ortega‐Paz, L., Franchi, F., Rollini, F., Galli, M., Been, L. F., Ghanem, G., Shalhoub, A., Ossi, T., Rivas, A., Zhou, X., et al. (2023) · Thrombosis and Haemostasis · doi:10.1055/a-2098-6639 · Cited by 10
Quality laboratory issues in bleeding disorders
Funk, D. M. A., Mammen, J., Nair, S. C., & Montalvão, S. A. D. L. (2016) · Haemophilia · doi:10.1111/hae.12991 · Cited by 10
Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
Song, Z., Cao, H., Wu, H., Qi, W., Tang, M., Yang, S., Liu, Y., & Qin, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8559 · Cited by 11
Management of epistaxis in patients on novel oral anticoagulation therapy
Ho, J. P. K., Bari, N., & Riffat, F. (2020) · The Journal of Laryngology & Otology · doi:10.1017/s0022215120000754 · Cited by 10
Low‐dose versus standard‐dose four‐factor prothrombin complex concentrate for factor‐Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage
Cascone, A. E., Daley, M. J., Pan, N., Padilla‐Tolentino, E., & Milling, T. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2525 · Cited by 10
Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
Rauch, S., Müller, H., Dreyhaupt, J., Ludolph, A. C., Kassubek, J., & Althaus, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123399 · Cited by 10
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
Nitta, K., Imamura, H., Yashio, A., Kashima, S., & Mochizuki, K. (2016) · Case Reports in Critical Care · doi:10.1155/2016/7938062 · Cited by 10
Embolic Stroke of Undetermined Source in Latin America
Cantú-Brito, C. G., Silva, G. S., & Ameriso, S. F. (2017) · The Neurologist · doi:10.1097/nrl.0000000000000128 · Cited by 10
Optimización perioperatoria del paciente anciano con fractura osteoporótica de cadera
Bengoa, F. J., Carrasco, M., Amenábar, P. P., Schweitzer, D., Botello, E., & Klaber, I. (2017) · Revista médica de Chile · doi:10.4067/s0034-98872017001101437 · Cited by 11
Andexanet alfa for the treatment of hemorrhage
Cervi, A. L., & Crowther, M. A. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1532287 · Cited by 10
Self-citation
Human platelet lysate: a potential therapeutic for intracerebral hemorrhage
Qiu, D., Wang, L., Wang, L., & Dong, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1517601 · Cited by 10
Acute management of spontaneous intracerebral hemorrhage (ICH) in the emergency department
Puissant, M. M., & Ganti, L. (2026) · International Journal of Emergency Medicine · doi:10.1186/s12245-026-01126-z · Cited by 9
Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials
Garg, J., Chaudhary, R., Krishnamoorthy, P. M., Palaniswamy, C., Shah, N. N., Bozorgnia, B., & Natale, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.05.059 · Cited by 9
Reversal Agents for the Direct Oral Anticoagulants
Ansell, J. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.006 · Cited by 9
A framework for managing severe DOAC-related bleeding: Recognize, Reverse, Resume, Reduce
Cormier, S., & Siegal, D. M. (2024) · Thrombosis Update · doi:10.1016/j.tru.2024.100165 · Cited by 9
Self-citation
Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience
Klute, K. A., DeFilippis, E. M., Shillingford, K., Chapin, J. C., & DeSancho, M. T. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1337-4 · Cited by 9
Which Factors Influence Resident Physicians to Prescribe NOACs to Patients with Non-Valvular Atrial Fibrillation?
Oqab, Z., McIntyre, W. F., Hopman, W. M., & Baranchuk, A. M. (2016) · Europe PMC (PubMed Central) · doi:10.4022/jafib.1462 · Cited by 9
The Reversal of Direct Oral Anticoagulants in Animal Models
Honickel, M., Akman, N., & Grottke, O. (2017) · Shock · doi:10.1097/shk.0000000000000848 · Cited by 9
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation
Norby, F. L., & Alonso, Á. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0025 · Cited by 9
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation
Oertel, L. B., & Fogerty, A. E. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12494 · Cited by 9
Apixaban Auto-intoxication: Toxicokinetics and Coagulation Tests
Mast, L., Verheul, R. J., Reijnen, R., van Rossen, R. C. J. M., Overdiek, J. W. P. M., & Wilms, E. B. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0474 · Cited by 9
Antithrombotic Drugs
Jaffer, I., & Weitz, J. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00149-9 · Cited by 9
Andexanet Alfa for Reversal of Factor Xa Inhibitors: A Critical Review of the Evidence
Abdulrehman, J., Eikelboom, J. W., & Siegal, D. M. (2019) · Future Cardiology · doi:10.2217/fca-2019-0038 · Cited by 9
Self-citation
Rationale and Design of the Randomized Controlled Trial of New Oral Anticoagulants Versus Warfarin for Post Cardiac Surgery Atrial Fibrillation
Osho, A. A., Moonsamy, P., Ethridge, B. R., Leya, G. A., D’Alessandro, D. A., Jassar, A. S., Villavicencio, M. A., Melnitchouk, S. I., Tolis, G., Langer, N. B., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004459 · Cited by 9
Outcomes Associated With 4‐Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients
Highsmith, E. A., Morton, C., Varnado, S., Donahue, K. R., Sulhan, S., & Lista, A. D. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1779 · Cited by 9
Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
Rodriguez, V., Stanek, J. R., Kerlin, B. A., & Dunn, A. L. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221078842 · Cited by 9
In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
Brinkman, H. J. M., Zuurveld, M. G., & Meijers, J. C. M. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12775 · Cited by 9
Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 9
Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation
Dhaese, S. A. M., & Vriese, A. S. D. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.01.007 · Cited by 9

Authors: Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A.
Affiliations: Population Health Research Institute (CA)
Portola Pharmaceuticals (United States) (US)
McMaster University (CA)
ORCID: Siegal, Deborah M.
Connolly, Stuart J.
Lu, Genmin
Conley, Pamela B.
Wiens, Brian L.
Mathur, Vandana S.
Crowther, Mark A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-12-17
Volume: 373
Issue: 25
Pages: 2413-2424
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1510991
OpenAlex: W2174386486
Cited by: 1,047
References: 22
Citations by year: 2026: 21 · 2025: 34 · 2024: 48 · 2023: 56 · 2022: 44 · 2021: 57 · 2020: 91 · 2019: 126 · 2018: 133 · 2017: 175 · 2016: 249 · 2015: 11
FWCI: 137.31
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: andexanet alfa, factor Xa inhibitors, apixaban, rivaroxaban, anticoagulant reversal, bleeding complications, anti-Xa activity, thrombin generation, unbound drug concentration, D-dimer, prothrombin fragments, older adults, drug safety, pharmacokinetics, pharmacodynamics, thromboprophylaxis, thrombolysis
MeSH terms: Rivaroxaban, Administration, Oral, Aged, Antidotes, Blood Coagulation, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Prothrombin, Pyrazoles, Pyridones, Recombinant Proteins, Factor Xa, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks